Literature DB >> 32492869

Development and Characterization of Liquisolid Tablets Based on Mesoporous Clays or Silicas for Improving Glyburide Dissolution.

Marzia Cirri1, Paola Mura1, Maurizio Valleri2, Letizia Brunetti1.   

Abstract

The aim of this work was to evaluate the effectiveness of mesoporous clays or silicas to develop fast-dissolving glyburide tablets based on a liquisolid approach. Selected clay (Neusilin®US2) and silica (Aeroperl®300) allowed preparation of innovative drug liquisolid systems containing dimethylacetamide or 2-pyrrolidone as drug solvents, without using coating materials which are necessary in conventional systems. The obtained liquisolid powders were characterized for solid-state properties, flowability, compressibility, morphology, granulometry, and then used for directly compressed tablet preparation. The developed liquisolid tablets provided a marked drug dissolution increase, reaching 98% dissolved drug after 60 min, compared to 40% and 50% obtained from a reference tablet containing the plain drug, and a commercial tablet. The improved glyburide dissolution was attributed to its increased wetting properties and surface area, due to its amorphization/solubilization within the liquisolid matrix, as confirmed by DSC and PXRD studies. Mesoporous clay and silica, owing to their excellent adsorbent, flow, and compressibility properties, avoided use of coating materials and considerably improved liquid-loading capacity, reducing the carrier amount necessary to obtain freely flowing powders. Neusilin®US2 showed a superior performance than Aeroperl®300 in terms of the tablet's technological properties. Finally, simplicity and cost-effectiveness of the proposed approach make it particularly advantageous for industrial scale-up.

Entities:  

Keywords:  Neusilin; aeroperl; dissolution improvement; glyburide; liquisolid technique; mesoporous clay

Year:  2020        PMID: 32492869     DOI: 10.3390/pharmaceutics12060503

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  2 in total

1.  Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design.

Authors:  Faiza Naureen; Yasar Shah; Sayyed Ibrahim Shah; Muhammad Abbas; Inayat Ur Rehman; Salar Muhammad; Hamdullah Hamdullah; Khang Wen Goh; Fazli Khuda; Amjad Khan; Siok Yee Chan; Mehwish Mushtaq; Long Chiau Ming
Journal:  Molecules       Date:  2022-06-22       Impact factor: 4.927

2.  Clay-Based Pharmaceutical Formulations and Drug Delivery Systems.

Authors:  Fátima García-Villén; César Viseras
Journal:  Pharmaceutics       Date:  2020-11-25       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.